AI-assisted, source-referenced information. Independent clinical review is pending.
At a glance

Foundayo contains orforglipron and was authorised in the UK on 10 August 2026 for adult weight management and type 2 diabetes. Its food and water instructions differ from oral semaglutide, and its marketed tablet strengths differ from doses quoted in some trials.

Active ingredientOrforglipron
FormulationDaily tablet
SupplyPrescription only

A different molecule within the GLP-1 family

Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. It is not oral tirzepatide and does not become the same medicine as Mounjaro because both are made by Lilly. The MHRA authorised Foundayo on 10 August 2026. Its weight-management indication covers adults with an initial BMI of at least 30, or at least 27 with a relevant weight-related condition, alongside diet and activity changes.

The approval also includes type 2 diabetes, but this hub concerns adult weight management. If you have diabetes, treatment selection must account for glucose control and the rest of your diabetes medicines. Distinguishing the reason for treatment helps avoid importing a dose, study result or NHS access rule from a different clinical setting.

Sources: MHRA: UK authorises orforglipron for weight management and type 2 diabetes

Meal flexibility is a practical difference

The UK instructions allow Foundayo once daily at any time, without food or water restrictions. Tablets should be swallowed whole. This contrasts with oral semaglutide's fasting and waiting routine, but it does not make Foundayo suitable for everyone or establish a superior clinical effect. Convenience is one part of a prescribing discussion.

Consider how you will remember a daily medicine, keep the original packaging available and organise repeats. If taking it alongside other tablets seems attractive, first ask a pharmacist to check the whole list. A flexible relationship with meals does not mean an absence of interactions. Include occasional prescriptions, supplements and herbal products in that discussion, rather than listing only the medicines you take every morning.

Sources: Eli Lilly / electronic medicines compendium: Foundayo: patient information leaflet; Eli Lilly / electronic medicines compendium: Foundayo: UK Summary of Product Characteristics, revised 3 November 2026

Use UK tablet strengths, not trial capsule numbers

The marketed UK film-coated tablet strengths are 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg. The starting dose is 0.8 mg daily, with at least 30 days before each prescribed increase. The maximum is 17.2 mg daily, although an interacting medicine may require a different limit. Do not take several tablets to make a higher dose.

Some research reports use 6, 12 or 36 mg because the trials used a different capsule formulation. Those numbers should not appear as instructions to select or combine marketed tablets. When comparing an online price with a study, keep the formulation explicit. If a listing gives a research dose without identifying the licensed product being supplied, clarify it with the provider before relying on the comparison.

Sources: Eli Lilly / electronic medicines compendium: Foundayo: UK Summary of Product Characteristics, revised 3 November 2026; New England Journal of Medicine: ATTAIN-1: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

Read the evidence without turning it into a ranking

ATTAIN-1 studied adults without diabetes over 72 weeks. In the treatment-regimen analysis, the highest research-dose group had an average weight reduction of 11.2%, compared with 2.1% with placebo. The study used dose escalation and lifestyle support. Gastrointestinal adverse effects were common, and some participants stopped treatment because of adverse events.

ATTAIN-2 studied people with type 2 diabetes and therefore answers a different question. Its findings should not be blended with ATTAIN-1 to produce a single prediction for every user. Nor do these placebo-controlled studies prove that Foundayo is better or worse for an individual than a particular injection or oral semaglutide. A useful decision connects the evidence to medical history, tolerability, daily routine and achievable ongoing care.

Sources: New England Journal of Medicine: ATTAIN-1: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment; The Lancet / PubMed: ATTAIN-2: Orforglipron for obesity in people with type 2 diabetes

Interaction checks deserve particular attention

Foundayo has clinically relevant interactions with medicines that affect its processing in the body. Examples in the UK information include certain antibiotics, antifungals, antivirals, anticonvulsants and St John's wort. Some combinations should be avoided; others can require prescribed dose limits or changes to another medicine. Do not apply these adjustments yourself. Ask for a fresh check whenever a new medicine is added.

Oral hormonal contraception may be less effective: the UK advice is a non-oral method or additional barrier contraception for 30 days after starting and after each increase. Pregnancy planning and breastfeeding also require discussion. Severe persistent abdominal pain needs urgent assessment. Persistent vomiting or diarrhoea can cause dehydration, and a tablet formulation does not remove that risk.

Sources: Eli Lilly / electronic medicines compendium: Foundayo: UK Summary of Product Characteristics, revised 3 November 2026; Eli Lilly / electronic medicines compendium: Foundayo: patient information leaflet; NHS: Dehydration: symptoms and when to get help

What to establish before an ongoing commitment

Ask the provider to explain who reviews dose increases, how interactions are checked and how quickly clinical queries are answered. Keep a record of the product, strength and start date, especially if your usual GP is not the prescriber. Tell the team planning any surgery or sedation that you are taking a GLP-1 medicine. A delivery service and a clinical follow-up service are different things; clarify what is included.

Compare the price of the same tablet strength and quantity, then examine the repeat cost and any commitment. Regulatory approval does not itself create NHS funding or guarantee retail availability. Avoid choosing treatment around the cheapest starter pack if you cannot see how future reviews and repeat supplies will be arranged. Raise affordability early so it can be considered as part of a sustainable plan.

Sources: General Pharmaceutical Council and UK health organisations: How to keep safe when getting medicines or treatment online; MHRA: UK authorises orforglipron for weight management and type 2 diabetes; MHRA: GLP-1 medicines: potential aspiration risk during anaesthesia or deep sedation

Compare prices for your prescribed dose

UK tablets start at 0.8 mg daily, then 2.5 mg after at least 30 days. Further steps are 5.5, 9, 14.5 and 17.2 mg, each requiring at least 30 days and a clinical decision. Interacting medicines can change the permitted dose.

These are first-order price observations, not prescribing recommendations. Repeat costs and additional fees may differ.

Questions, answered.

Is Foundayo the same as a Wegovy tablet?

No. Foundayo contains orforglipron; Wegovy tablets contain semaglutide. They have different administration instructions, strengths and interaction considerations.

Sources: MHRA: UK authorises orforglipron for weight management and type 2 diabetes; MHRA: First GLP-1 tablet for weight loss approved in the UK

Why does a trial mention 36 mg when the UK maximum tablet is 17.2 mg?

The research capsule and marketed film-coated tablet are different formulations. Use the licensed tablet prescription and leaflet, not a trial number, to identify your dose.

Sources: Eli Lilly / electronic medicines compendium: Foundayo: UK Summary of Product Characteristics, revised 3 November 2026

Does no fasting requirement mean no medicine interactions?

No. Food instructions and drug interactions are separate issues. Have all regular, occasional and non-prescription products checked by a pharmacist or prescriber.

Sources: Eli Lilly / electronic medicines compendium: Foundayo: patient information leaflet

Sources & further reading

Original sources for this guide. Source checks are not independent clinical review.

  1. UK authorises orforglipron for weight management and type 2 diabetesMHRA · Accessed 19 November 2026
  2. Foundayo: patient information leafletEli Lilly / electronic medicines compendium · Accessed 19 November 2026
  3. Foundayo: UK Summary of Product Characteristics, revised 3 November 2026Eli Lilly / electronic medicines compendium · Accessed 19 November 2026
  4. ATTAIN-1: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity TreatmentNew England Journal of Medicine · Accessed 19 November 2026
  5. ATTAIN-2: Orforglipron for obesity in people with type 2 diabetesThe Lancet / PubMed · Accessed 19 November 2026
  6. Dehydration: symptoms and when to get helpNHS · Accessed 19 November 2026
  7. How to keep safe when getting medicines or treatment onlineGeneral Pharmaceutical Council and UK health organisations · Accessed 19 November 2026
  8. GLP-1 medicines: potential aspiration risk during anaesthesia or deep sedationMHRA · Accessed 19 November 2026
  9. First GLP-1 tablet for weight loss approved in the UKMHRA · Accessed 19 November 2026